MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3390/jpm16040176

Медицинская библиотека · Journal of personalized medicine · 2026

Molecular Oncodiagnostics in Precision Oncology: Integrating Tumor Transcriptomics, Patient Pharmacogenetics, and Ex Vivo Chemoresistance Testing to Improve Individual Chemotherapy Response.

Rusciano Dario

СтатьяОбзорПеревод в очереди

Аннотация

Background

Precision oncology has traditionally relied on genomic biomarkers to guide therapy selection; however, static molecular profiling often fails to predict real-world responses to cytotoxic chemotherapy. Increasing evidence suggests that treatment outcomes are determined by the interaction between tumor-intrinsic biology and host-specific pharmacology. Functional ex vivo platforms, including patient-derived organoids and tumor slice cultures, provide a complementary phenotypic readout of drug sensitivity that reflects tumor architecture and microenvironmental interactions.

Methods

This narrative review integrates recent experimental, translational, and clinical evidence on molecular oncodiagnostics combining tumor transcriptomics, germline pharmacogenetics, and ex vivo drug sensitivity testing. Relevant literature was identified through targeted searches of major biomedical databases, focusing on studies describing multi-omic predictive models, functional precision oncology platforms, and patient-derived tumor models.

Results

Converging data indicate that integrated oncodiagnostic strategies can improve prediction of chemotherapy response beyond genomics-only approaches. Transcriptomic profiling captures dynamic pathway activity and resistance programs, pharmacogenetic testing informs host-specific toxicity and dosing constraints, and ex vivo assays enable direct phenotypic validation of drug efficacy. Together, these complementary approaches provide a biologically grounded framework for individualized therapy selection.

Conclusions

The convergence of molecular profiling and functional phenotyping represents an emerging paradigm in precision oncology. Integrating multi-omic and functional data may enhance treatment prediction and reduce ineffective therapy, although prospective validation and standardization remain necessary for routine clinical implementation.

Для цитирования: Rusciano Dario. Molecular Oncodiagnostics in Precision Oncology: Integrating Tumor Transcriptomics, Patient Pharmacogenetics, and Ex Vivo Chemoresistance Testing to Improve Individual Chemotherapy Response.. Journal of personalized medicine. 2026. DOI: 10.3390/jpm16040176.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.